title: Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
abstract: Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary mineralization of the calcified matrix remains unclear. We examined the effects of bisphosphonates on both the trabecular architecture and matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one receiving risedronate and the other alendronate at 5-6 times the clinical dose for osteoporosis treatment. After one year, the dogs were killed, and samples from the first lumbar vertebrae were examined using a combination of micro-computed tomography, finite element modeling, and mechanical testing. By combining these methods, we examined the treatment effects on the calcified matrix and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent Young's modulus, decreased bone turnover, increased calcified matrix density, and increased microdamage. We could not detect any change in the effective Young's modulus of the calcified matrix in the bisphosphonate treated groups. The observed increase in apparent Young's modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calcified matrix modulus. We hypothesize that the expected increase in the Young's modulus of the calcified matrix due to the increased calcified matrix density was counteracted by the accumulation of microdamage.
authors.affiliation: Erasmus Orthopaedic Research Laboratory, Erasmus MC, University Medical Centre of Rotterdam, EE1614, P.O. Box 1738, DR, Rotterdam 3000, The Netherlands.
authors.forename: J S
authors.initials: JS
authors.lastname: Day
authors.forename: M
authors.initials: M
authors.lastname: Ding
authors.forename: P
authors.initials: P
authors.lastname: Bednarz
authors.forename: J C
authors.initials: JC
authors.lastname: van der Linden
authors.forename: T
authors.initials: T
authors.lastname: Mashiba
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: C C
authors.initials: CC
authors.lastname: Johnston
authors.forename: D B
authors.initials: DB
authors.lastname: Burr
authors.forename: I
authors.initials: I
authors.lastname: Hvid
authors.forename: D R
authors.initials: DR
authors.lastname: Sumner
authors.forename: H
authors.initials: H
authors.lastname: Weinans
mesh_terms: D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D001857:Bone Matrix / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects*; D002113:Calcification, Physiologic / Q000187:drug effects; D004285:Dogs; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005260:Female; D000068296:Risedronic Acid
chemical_list: D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate